CURRENT
ISSUE
1590
January 27, 2020

Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood.1,2 A study in a large Danish cohort found that ADHD was associated with higher mortality rates in children, adolescents, and adults, mainly due to accidents.3 Pharmacologic treatment of ADHD in children has been reported to decrease the risk of substance abuse in adolescents, and use of ADHD medications in adults has been associated with a reduced risk of serious traffic...  Continue reading

More from Issue 1590
Previous Issue: 1589      January 13, 2020
Coming Soon
Istradefylline (Nourianz) for Parkinson's Disease
Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
Brolucizumab (Beovu) for Age-Related Macular Degeneration
Drugs for Depression
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
 Tweets
FROM
ISSUE
1590

The FDA has approved tafamidis, an oral transthyretin stabilizer, in 2 different formulations (see Table 1) for treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Tafamidis is the first drug to be approved in the US for this indication. Patisiran (Onpattro), a transthyretin-directed small interfering RNA, and inotersen (Tegsedi), a transthyretin-directed antisense oligonucleotide, were both recently approved for hereditary transthyretin amyloid polyneuropathy.

THE DISEASE — ATTR-CM ... Continue reading